REPORTS

Let’s Pullulate and Expand Your Business

Axitinib Market - Global Professional Analysis and Forecast to 2026

Nov 14, 2019  |  177 PAGES  |  REPORT CODE: CMM235937
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Axitinib market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.1% during the forecast period.

This report presents the market size and development trends by detailing the Axitinib market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Axitinib market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Axitinib industry and will help you to build a panoramic view of the industrial development.

Axitinib Market, By Type:

  • Injection

  • Others

Axitinib Market, By Application:

  • Renal Cancer Treatment

  • Others

Some of the leading players are as follows:

  • Alnylam Pharmaceuticals

  • Pfizer

  • CASI Pharmaceuticals

  • Biocon

  • Genentech

  • Celgene Corporation

  • Bionomics

  • Fujifilm Kyowa Kirin Biologics

  • Acceleron Pharma

  • Angstrom Pharmaceuticals

  • Five Prime Therapeutics

  • Amgen

  • Allergan

  • Enzon Pharmaceuticals

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Axitinib Market: Technology Type Analysis

  • 4.1 Axitinib Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Axitinib Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Injection

    • 4.3.2 Others

5 Axitinib Market: Product Analysis

  • 5.1 Axitinib Product Market Share Analysis, 2018 & 2026

  • 5.2 Axitinib Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Axitinib Market: Application Analysis

  • 6.1 Axitinib Application Market Share Analysis, 2018 & 2026

  • 6.2 Axitinib Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Renal Cancer Treatment

    • 6.3.2 Others

7 Axitinib Market: Regional Analysis

  • 7.1 Axitinib Regional Market Share Analysis, 2018 & 2026

  • 7.2 Axitinib Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Alnylam Pharmaceuticals

    • 9.1.1 Alnylam Pharmaceuticals Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Pfizer

    • 9.2.1 Pfizer Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 CASI Pharmaceuticals

    • 9.3.1 CASI Pharmaceuticals Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Biocon

    • 9.4.1 Biocon Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Genentech

    • 9.5.1 Genentech Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Celgene Corporation

    • 9.6.1 Celgene Corporation Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Bionomics

    • 9.7.1 Bionomics Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Fujifilm Kyowa Kirin Biologics

    • 9.8.1 Fujifilm Kyowa Kirin Biologics Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Acceleron Pharma

    • 9.9.1 Acceleron Pharma Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Angstrom Pharmaceuticals

    • 9.10.1 Angstrom Pharmaceuticals Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Five Prime Therapeutics

    • 9.11.1 Five Prime Therapeutics Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Amgen

    • 9.12.1 Amgen Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Allergan

    • 9.13.1 Allergan Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Enzon Pharmaceuticals

    • 9.14.1 Enzon Pharmaceuticals Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

 

The List of Tables and Figures (Totals 67 Figures and 160 Tables)

  • Figure Injection Axitinib market, 2015 - 2026 (USD Million)

  • Figure Others Axitinib market, 2015 - 2026 (USD Million)

  • Figure Renal Cancer Treatment market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Axitinib market, by country, 2015 - 2026 (USD Million)

  • Table North America Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table North America Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table North America Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Canada Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Canada Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Europe Axitinib market, by country, 2015 - 2026 (USD Million)

  • Table Europe Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Europe Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Europe Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Germany Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Germany Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table France Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table France Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Italy Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Italy Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Spain Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Spain Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Axitinib market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table China Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table China Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Japan Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Japan Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table India Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table India Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Axitinib market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table MEA Axitinib market, by country, 2015 - 2026 (USD Million)

  • Table MEA Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table MEA Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table MEA Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Axitinib market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Axitinib market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Axitinib market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Alnylam Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table CASI Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biocon Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Genentech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Celgene Corporation Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bionomics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Fujifilm Kyowa Kirin Biologics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Acceleron Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Angstrom Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Five Prime Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Allergan Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Enzon Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top